Combination bronchodilator therapy in COPD.
نویسنده
چکیده
منابع مشابه
Combination therapy for COPD: emerging evidence from recent clinical trials
Chronic obstructive pulmonary disease (COPD) is a heterogeneous syndrome encompassing the clinical presentations of chronic bronchitis and emphysema. Moderate-to-severe COPD is estimated to affect 80 million people worldwide. The diagnosis of COPD is made using spirometry, demonstrating the presence of obstruction that does not completely reverse with the administration of an inhaled bronchodil...
متن کاملRole of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
Once-daily dual-bronchodilator therapy with combined indacaterol and glycopyrronium bromide in one device (Ultibro, Breezhaler), often called QVA149, was first approved in 2013 in Japan and Europe. As of November 2014, more than 40 countries had approved this medication except for the USA. This is the first dual bronchodilator in one device. Now, the Breezhaler is the only device that can provi...
متن کاملTriple therapy for the management of COPD: a review.
Triple therapy for COPD consists of a long-acting anti-cholinergic bronchodilator, a long-acting beta-agonist bronchodilator, and an inhaled corticosteroid. Guidelines from the Canadian Thoracic Society advocate triple therapy for some patients with moderate-to-severe COPD. The objective of this review was to evaluate the evidence based clinical efficacy of triple therapy compared to dual bronc...
متن کاملChanges in oscillatory impedance and nitrogen washout with combination fluticasone/salmeterol therapy in COPD.
INTRODUCTION Combination inhaled corticosteroid/long-acting bronchodilator (ICS/LABA) therapy reduces the exacerbation rate and improves spirometry and quality of life in COPD. We hypothesized that ICS/LABA therapy also improves small airway function measured by FOT. METHODS 14 subjects with COPD were commenced on combination fluticasone propionate/salmeterol therapy for 3 months. At baseline...
متن کاملRandomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD
Long-acting muscarinic antagonist (LAMA) or long-acting β2-agonist (LABA) bronchodilators and their combination are recommended for the maintenance treatment of chronic obstructive pulmonary disease (COPD). Although the efficacy of LAMAs and LABAs has been well established through randomized controlled trials (RCTs), questions remain regarding their cardiovascular (CV) safety. Furthermore, whil...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Chest
دوره 107 5 Suppl شماره
صفحات -
تاریخ انتشار 1995